Hemerion Therapeutics key facts
as of Oct 2026- Operator of a biotechnology platform intended to treat resistant tumors using proprietary photosensitizing molecules paired with advanced laser light technologies.
- Hemerion Therapeutics is valued at approximately $26.2M as of Oct 2026 (last reported valuation).
- It has raised $14.2M; the latest was Later Stage VC ($39.5M) in May 2025.
- Notable investors include Bpifrance, France 2030, Finorpa, Finovam Gestion, Fira Group — 9 tracked in total.
- Status: Privately Held (backing).
Hemerion Therapeutics's last reported valuation, May 2025. Nothing priced has surfaced since.
- ·Watch Hemerion Therapeutics: the Monday email on marks, rounds and moves
Hemerion Therapeutics funding rounds
No funding rounds for Hemerion Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Hemerion Therapeutics valuation
Hemerion Therapeutics's last reported valuation was $26.2 million in May 2025. No priced round, secondary trade or fund mark has surfaced since.
Hemerion Therapeutics investors
9 investors are on record for Hemerion Therapeutics, including Bpifrance, France 2030, Finorpa and Finovam Gestion.
About Hemerion Therapeutics
Operator of a biotechnology platform intended to treat resistant tumors using proprietary photosensitizing molecules paired with advanced laser light technologies. The company offers a unique combination of photosensitizing compounds and controlled laser delivery, enabling oncologists focusing on hard-to-treat brain tumors to achieve highly precise tumor targeting.
- Sector
- Healthcare
- HQ
- Villeneuve-d'Ascq, France
- Founded
- 2020
- Employees
- 15
- Website
- hemerion.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.